Released Nov 15, 2021, before the open
10-Q filed Nov 15, 2021, 46 days after period end · 0001193125-21-329068
Q3 2021 · 10-Q
Revenue—
Net Income-$3.90M-$3.90M N/M vs Q3 2020N/M vs Q2 2021
EPS Diluted-$0.10-$0.10 N/M vs Q3 2020N/M vs Q2 2021
Operating Income-$3,935,000N/M
Operating Cash Flowderived-$7,688,000N/M
Free Cash Flowderived-$7,696,000—
What the release said
The release
Same quarter
| Metric | Q3 2021 | Q3 2020 |
|---|---|---|
| Net Income | -$3.90M | -$2.49M |
| EPS Diluted | -$0.10 | -$5.94 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Acumen Pharmaceuticals, Inc. · CIK 1576885 · Engraved from SEC EDGAR